Last reviewed · How we verify
NCT04819490
A UK Multicentre, Health-Related Quality of Life Study for Children and Adolescents With XLH
trial in X-Linked Hypophosphataemia in 32 participants. Completed in 29 July 2022.
29 July 2022
Quick facts
| Lead sponsor | Kyowa Kirin Pharmaceutical Development Ltd |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 32 |
| Start date | 1 April 2021 |
| Primary completion | 29 July 2022 |
| Estimated completion | 29 July 2022 |
| Sites | 6 locations across United Kingdom |
Conditions studied
- X-Linked Hypophosphataemia — all drugs for X-Linked Hypophosphataemia →
Sponsor
Kyowa Kirin Pharmaceutical Development Ltd — full company profile →
Who can join
Adults 4 to 18, any sex, with X-Linked Hypophosphataemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to provide Health-related Quality of Life (HRQoL) data from children and adolescents with growing skeletons in the United Kingdom (UK), including those treated with burosumab or alternative XLH treatment, as part of an updated submission to the SMC in early 2023. This study will utilise data from a subset of UK sites already within the XLH Registry (including participating Scottish sites) and collect additional HRQoL data within these sites (that are otherwise not included in the wider XLH Registry protocol). The HRQoL data will enable the calculation of HRQoL to derive the HRQoL utility estimates in children and adolescents with growing skeletons for the RSS health states, hence addressing an area of uncertainty.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04819490
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Kyowa Kirin Pharmaceutical Development Ltd trials
Trials by the same sponsor.
- NCT05455931 — Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER) · active not recruiting
- NCT05181839 — A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth · completed
- NCT04188964 — Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age · Phase 1, PHASE2 · completed
- NCT03920072 — Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH · Phase 3 · completed
- NCT03638440 — Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC. · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04819490 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kyowa Kirin Pharmaceutical Development Ltd
- Last refreshed: 25 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04819490.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing